Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784767 · ClinicalTrials.gov registry record · Phase 1
PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT04784767: Completed Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
NCT04784767 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04784767, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the SpFN COVID-19 vaccine with Army Liposomal Formulation QS21 (ALFQ) adjuvant in healthy adults ages 18-55.
Primary Outcome
Post-vaccination reactions including erythema, induration, pain/tenderness, swelling, limitation of arm movement, fever, tiredness, chills, rash, myalgia, arthralgia, nausea, and headache.
Interventions
- BIOLOGICAL 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- DRUG Sodium chloride, USP, for injection (0.9% NaCl)
- BIOLOGICAL 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-04-05 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 1 |
What the finished NCT04784767 record still lists
NCT04784767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 3 interventions - of which 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) is the first listed.
NCT04784767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04784767 about?
NCT04784767 is a clinical study titled "PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19". The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the SpFN COVID-19 vaccine with Army Liposomal Formulation QS21 (ALFQ) adjuvant in healthy adults ages 18-55.
What is the current status of trial NCT04784767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-04-05. Estimated completion is 2023-10-30.
What interventions are being tested in trial NCT04784767?
The interventions under investigation include: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) (BIOLOGICAL), Sodium chloride, USP, for injection (0.9% NaCl) (DRUG), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04784767?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04784767's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI